DNAA Stock Price, News & Analysis

PureTech Health (LSE: PRTC, Nasdaq: PRTC) announced nominees for the board of directors for its Founded Entity, Akili Interactive, following its merger with Social Capital Suvretta Holdings Corp. I (Nasdaq: DNAA). The board will include industry leaders such as BJ Jones, Christine Lemke, Ken Ehlert, and Chamath Palihapitiya, who bring extensive experience in biopharmaceuticals and healthcare. This move marks a significant step toward Akili’s goal of scaling digital therapeutics, particularly as it approaches market introduction of its first product.

Akili Interactive announced new director nominees for its upcoming board following its business combination with Social Capital Suvretta Holdings Corp. I (NASDAQ: DNAA). The nominees include industry leaders such as BJ Jones and Chamath Palihapitiya. The new board will consist of seven directors, aimed at guiding Akili in commercializing digital therapeutics. The merger's closing is subject to customary conditions, and common stock is expected to trade under the symbol "AKLI". The leadership intends to leverage their extensive expertise for growth in the digital medicine sector.

Roblox (NYSE:RBLX) and Akili Interactive are partnering to integrate cognitive medicine into everyday life through gaming. This collaboration aims to connect medical treatments with patient experiences in virtual environments. Initially, they will establish a Roblox rewards exchange for Akili’s EndeavorRx® treatment, an FDA-cleared prescription video game for ADHD in children. The partnership aspires to reshape the patient experience by making treatment engaging and enjoyable, enhancing cognitive health through innovative digital interactions.

PureTech Health reported a solid capital base with cash equivalents of $465.7 million as of December 31, 2021. The company has a robust pipeline featuring 27 therapeutics, with 11 clinical trials initiated in 2021. Notably, PureTech's Founded Entities have achieved significant milestones, including FDA marketing approvals for two products. The company is evaluating capital allocation strategies to enhance shareholder value, including potential returns through dividends or buybacks. Its cash runway extends into 2025, supporting ongoing development across its pipeline.

PureTech Health announced that Akili’s AKL-T03 digital therapeutic demonstrated a statistically significant improvement in sustained attention in adults with major depressive disorder (MDD) when combined with antidepressant therapy, as published in the American Journal of Psychiatry. The STARS-MDD trial involved 80 adults and showed a 0.005 significance level. This digital therapeutic builds on the technology of EndeavorRx, already FDA-cleared for treating children with ADHD. Akili aims to fill a gap in treating cognitive impairments associated with depression, a condition affecting over 16 million Americans.

Akili Interactive announced positive results from the STARS-MDD trial of AKL-T03, a digital therapeutic for attention impairments in adults with major depressive disorder (MDD). The study demonstrated a statistically significant improvement in sustained attention compared to a control group (p=0.005). Out of 80 adult participants, the treatment showed promising potential when used alongside antidepressants. Importantly, no serious adverse events were reported, indicating a favorable safety profile. AKL-T03 aims to address cognitive impairments often overlooked in MDD therapies.

BOSTON--(BUSINESS WIRE)--Akili Interactive, a leading digital medicine company, announced its management will present at Chardan’s Prescription Digital Therapeutics Half-Day Summit on April 11, 2022. The company is pioneering cognitive treatments using advanced technologies, treating cognitive impairments like a clinical drug yet through engaging video games. On January 26, 2022, Akili confirmed a merger with Social Capital Suvretta Holdings Corp. I (NASDAQ: DNAA), expected to close mid-2022, after which Akili's new ticker symbol will be AKLI.

PureTech Health announces Jon David as the new Chief Product Officer of its Founded Entity, Akili Interactive. With over 20 years in the gaming industry, David is expected to drive Akili's product pipeline, developing innovative cognitive treatments that feel like high-end entertainment. His leadership experience includes positions at Glu Mobile and PopCap Games, where he contributed to hit franchises. This strategic appointment underscores Akili's commitment to merging entertainment with therapeutic solutions as it prepares for its merger with Social Capital Suvretta Holdings Corp. I.

Akili Interactive has announced the appointment of Jon David as Chief Product Officer. With over 20 years in the video game industry, David aims to enhance Akili's strategy in developing cognitive treatments that feel like entertainment. Previously, he served at Glu Mobile and PopCap Games, contributing to notable franchises. CEO Eddie Martucci emphasized David’s innovative approach, which aligns with Akili's mission to create engaging therapeutic experiences. The company is set to merge with Social Capital Suvretta Holdings Corp. I (NASDAQ: DNAA), anticipated to complete in mid-2022.